

# 赤尾 幸博

所属 Affiliation

岐阜大学大学院連合創薬医療情報研究科・特任教授

(創薬科学専攻・寄附講座)

Yukihiro AKAO

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University; Specially-appointed Professor (Endowed Chair, Medicinal Sciences Division)

専門 Research Area	分子遺伝学、腫瘍医学、がん予防 Molecular Genetics, Medicinal Oncology, Cancer Prevention
研究課題 代表的な研究	<p>① <b>RNA 創薬：microRNA や siRNA を用いた癌の治療</b> 我々は大腸腫瘍における miRNA 発現プロファイルを作成し、大腸癌の発生、発育、進展に関わる miR-143 および miR-145 を見出した。これらががん抑制マイクロ RNA であることを明らかにした。さらに担癌ヌードマウスを用いて全身投与により著明な腫瘍縮小効果が確認した、現在 RNA 創薬への開発研究を進めている。さらにがん細胞が分泌する膜小胞マイクロ RNA の生物学的意義について研究を進めている。</p> <p>② <b>ファイトケミカルによるがんの未病医療</b> 多くの食物に含まれるファイトケミカルによる細胞死はミトコンドリアを標的にしてがん細胞をアポトーシスに誘導することを明らかにした。抗がん剤との併用効果について明らかにした。我々はがん予防に資する機能性食品の研究開発を進めている。植物のエキシゾーム miRNA の機能及び体内動態についても研究を進めている。</p>
Main Research Projects	<p>① <b>RNA drug discovery: Cancer treatment with microRNA (miRNA) and siRNA</b> We analyzed miRNA expression profiles in colorectal cancer and found that miR-143 and miR-145 are involved in the development, growth, and invasion of tumors. miR-143 and miR-145 are tumor suppressor miRNAs, and their systemic administration resulted in tumor reduction in a nude mouse model, suggesting their possible use in cancer therapy. Another focus of our research in this area is the biological significance of microvesicles released from cancer cells.</p> <p>② <b>Preemptive medicine of cancer using phytochemicals</b> We revealed that phytochemicals, which are contained in a variety of foods, induce apoptosis by targeting mitochondria. We have been researching and developing a functional food that contributes to cancer prevention. We also tried to disclose the contribution of food-oriented exosome to prevention of diseases.</p>
研究業績 (過去 5 年)	<ol style="list-style-type: none"><li>Maeda J, Jepson B, Sadahiro K, Murakami M, Sakai H, Heishima K, <b>Akao Y</b>, Kato TA. PARP deficiency causes hypersensitivity to Taxol through oxidative stress induced DNA damage. <i>Mutat Res.</i> 2023 Jun 2;827:111826. doi: 10.1016/j.mrfmmm. 2023. 111826. Online ahead of print. (IF:3.151, CS:5.3) 査読あり</li><li>Satake A, Minatoguchi S, Heishima K, Yasuda S, Murase H, Yoshizumi R, Komaki H, Baba S, Ojio S, Tanaka T, <b>Akao Y</b>, Minatoguchi S, Okura H. An Increase in Plasma MicroRNA-143 Levels in the Acute Phase Is Positively Correlated With Recovery of Cardiac Function in the Chronic Phase in Patients With Acute Myocardial Infarction. <i>Circ J.</i> 2023 May 25;87(6):824-833. doi: 10.1253/circj.CJ-22-0698. Epub 2023 Feb 11. (IF:3.3) 査読あり</li><li>Sugito N, Heishima K, <b>Akao Y</b>. Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells. <i>Mol Ther Nucleic Acids.</i> 2022 Sep 7;30:49-61. doi: 10.1016/j.omtn. 2022.09.001. eCollection 2022 Dec 13. (IF:10.18, CS:9.8) 査読あり</li><li>Nakagawa Y, <b>Akao Y</b>, Yamashita H, Tahara T, Funasaka K, Nagasaka M, Kuzuya T, Miyahara R, Hashimoto S, Shibata T, Hirooka Y. MicroRNA Profile of Human Small Intestinal Tumors Compared to Colorectal Tumors. <i>J Clin Med.</i> 2022 May 6;11(9):2604. doi: 10.3390/jcm11092604. (IF:4.96, CS:5.4) 査読あり</li><li>Inomata Y, Oh JW, Taniguchi K, Sugito N, Kawaguchi N, Hirokawa F, Lee SW, <b>Akao Y</b>, Takai S, Kim KP, Uchiyama K. Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. <i>Int J Mol Sci.</i> 2022 May 7;23(9):5230. doi: 10.3390/ijms23095230. (IF:5.6, CS:7.8) 査読あり</li></ol>

6. Inomata Y, Oh JW, Taniguchi K, Sugito N, Kawaguchi N, Hirokawa F, Lee SW, **Akao Y**, Takai S, Kim KP, Uchiyama K. Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. *Int J Mol Sci.* 2022 May 7;23(9):5230. (IF: 5.923, CS: 6.0) 査読あり
7. **Akao Y**, Terazawa R, Sugito N, Heishima K, Morikawa K, Ito Y, Narui R, Hamaguchi R, Nobukawa T. Understanding of cell death induced by the constituents of *Taxus yunnanensis* wood. *Sci Rep.* 2022 Apr 15;12(1):6282. (IF: 4.379, CS: 7.1) 査読あり
8. **Akao Y**, Kuranaga Y, Heishima K, Sugito N, Morikawa K, Ito Y, Soga T, Ito T. Plant hvu-MIR168-3p enhances expression of glucose transporter 1 (SLC2A1) in human cells by silencing genes related to mitochondrial electron transport chain complex I. *J Nutr Biochem.* 2022 Mar;101:108922. (IF: 6.048, CS: 9.7) 査読あり
9. Shimizu Y, Takeda-Kawaguchi T, Kuroda I, Hotta Y, Kawasaki H, Hariyama T, Shibata T, **Akao Y**, Kunisada T, Tatsumi J, Tezuka KI. Exosomes from dental pulp cells attenuate bone loss in mouse experimental periodontitis. *J Periodontal Res.* 2022 Jan;57(1):162-172.
10. Heishima K, Sugito N, Soga T, Nishikawa M, Ito Y, Honda R, Kuranaga Y, Sakai H, Ito R, Nakagawa T, Ueda H, **Akao Y**. Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis. *J Clin Invest.* 2021 Sep 1;131(17):e139933. (IF: 14.808, CS: 17.7) 査読あり
11. Fukada M, Matsuhashi N, Takahashi T, Sugito N, Heishima K, Yoshida K, **Akao Y**. Postoperative changes in plasma miR21-5p as a novel biomarker for colorectal cancer recurrence: A prospective study. *Cancer Sci.* 2021 Oct;112(10):4270-4280. (IF: 6.716, CS: 8.5) 査読あり
12. Tokumaru Y, Oshi M, Huyser MR, Yan L, Fukada M, Matsuhashi N, Futamura M, **Akao Y**, Yoshida K, Takabe K. Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer. *Sci Rep.* 2021 Jul 8;11(1):14134. (IF: 5.923, CS: 6.0) 査読あり
13. Konishi H, Hayashi M, Taniguchi K, Nakamura M, Kuranaga Y, Ito Y, Kondo Y, Sasaki H, Terai Y, **Akao Y**, Ohmichi M. The therapeutic potential of exosomal miR-22 for cervical cancer radiotherapy. *Cancer Biol Ther.* 2020 Dec 1;21(12):1128-1135. (IF: 4.742, CS: 8.3) 査読あり
14. Sugito N, Heishima K, Ito Y, **Akao Y**. Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3-FOXO1. *Cancers (Basel).* 2020 Nov 10;12(11):3312. (IF: 6.102, CS: 4.4) 査読あり
15. Taniguchi K, Uchiyama K, **Akao Y**. PTBP1-targeting microRNAs regulate cancer-specific energy metabolism through the modulation of PKM1/M2 splicing. *Cancer Sci.* 2021 Jan;112(1):41-50. *Cancer Sci.* (IF:6.716, CS:8.50) 査読あり
16. Fukada M, Matsuhashi N, Takahashi T, Sugito N, Heishima K, **Akao Y**, Yoshida K. Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients. *J Clin Med.* Aug 4;9(8):E2509. 2020. (IF:4.241, CS:7.07) 査読あり
17. Hashimoto M, Nakai T, Masutani T, Unno K, **Akao Y**. Improvement of Learning and Memory in Senescence-Accelerated Mice by S-Allylcysteine in Mature Garlic Extract. *Nutrients.* 2020 Jun 19;12(6):1834. (IF:4.008, CS:6.2) 査読あり
18. Tokumaru Y, Asaoka M, Oshi M, Katsuta E, Yan L, Narayanan S, Sugito N, Matsuhashi N, Futamura M, **Akao Y**, Yoshida K, Takabe K. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. *Int J Mol Sci.*, May 1;21(9):3213. 2020. (IF:5.923, CS:6.00) 査読あり
19. Tokumaru Y, Katsuta E, Oshi M, Sporn JC, Yan L, Le L, Matsuhashi N, Futamura M, **Akao Y**, Yoshida K, Takabe K. High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer. *Int J Mol Sci.*, Apr 26;21(9):3045. 2020. (IF:5.923, CS:6.00) 査読あり
20. Jung JH, Taniguchi K, Lee HM, Lee MY, Bandu R, Komura K, Lee KY, **Akao Y**, Kim KP. Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). *Sci Rep.*, Apr 9;10(1):6124. 2020. (IF:4.379, CS:7.2) 査読あり

21. Tokumaru Y, Takabe K, Yoshida K, **Akao Y**. Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview. *Cancer Sci.* 111(4):1076-1083, (2020). (IF:4.966, CS:4.60) 査読あり
22. Tokumaru Y, Oshi M, Katsuta E, Yan L, Satyananda V, Matsuhashi N, Futamura M, **Akao Y**, Yoshida K, Takabe K. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival. *Am J Cancer Res.* 10(3):897-907, (2020). (IF:4.710, CS:4.737) 査読あり
23. Yoshikawa R, Heishima K, Ueno Y, Kawade M, Maeda Y, Yoshida K, Murakami M, Sakai H, **Akao Y**, Mori T. Development of synthetic microRNA-214 showing enhanced cytotoxicity and RNase resistance for treatment of canine hemangiosarcoma. *Vet Comp Oncol.* 2020. (IF:2.390, CS:2.57) 査読あり
24. Taniguchi K, Wada SI, Ito Y, Hayashi J, Inomata Y, Lee SW, Tanaka T, Komura K, **Akao Y**, Urata H, Uchiyama K.  $\alpha$ -Aminoisobutyric Acid-Containing Amphipathic Helical Peptide-Cyclic RGD Conjugation as a Potential Drug Delivery System for MicroRNA Replacement Therapy in Vitro. *Mol Pharm.* 16(11):4542-4550, 2019. (IF:4.570, CS:4.70) 査読あり
25. Yamada NO, Heishima K, **Akao Y**, Senda T. Extracellular Vesicles Containing MicroRNA-92a-3p Facilitate Partial Endothelial-Mesenchymal Transition and Angiogenesis in Endothelial Cells. *Int J Mol Sci.* 7;20(18):4406, 2019. (IF:4.556, CS:4.32) 査読あり
26. Nakagawa Y, Kuranaga Y, Tahara T, Yamashita H, Shibata T, Nagasaka M, Funasaka K, Ohmiya N, **Akao Y**. Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors. *Cancer Sci.* 110(8): 2540-2548, 2019. (IF:4.966, CS:4.60) 査読あり
27. Tsujino T, Sugito N, Taniguchi K, Honda R, Komura K, Yoshikawa Y, Takai T, Minami K, Kuranaga Y, Shinohara H, Tokumaru Y, Heishima K, Inamoto T, Azuma H, **Akao Y**. MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer. *Cancer Sci.* 110(7):2189-2199, 2019. (IF:4.966, CS:4.60) 査読あり
28. Nishikawa M, Nakano S, Nakao H, Sato K, Sugiyama T, **Akao Y**, Nagaoka H, Yamakawa H, Nagase T, Ueda H. The interaction between PLEKHG2 and ABL1 suppresses cell growth via the NF- $\kappa$ B signaling pathway in HEK293 cells. *Cell Signal.* 61:93-107, 2019. (IF:4.880, CS:6.4) 査読あり
29. Yoshikawa Y, Taniguchi K, Tsujino T, Heishima K, Inamoto T, Takai T, Minami K, Azuma H, Miyata K, Hayashi K, Kataoka K, **Akao Y**. Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment. *Mol Ther Methods Clin Dev.* 20;13:290-302, 2019. (IF:4.533, CS:3.26) 査読あり
30. Yoshikawa R, Mori T, Noguchi S, **Akao Y**, Maruo K, Kitade Y. Synthetic microRNA-205 exhibited tumour suppression in spontaneous canine malignant melanoma by intratumoral injection. *Vet Comp Oncol.* 2019. (IF:2.27, CS:2.57) 査読あり
31. Tokumaru Y, Tajirika T, Sugito N, Kuranaga Y, Shinohara H, Tsujino T, Matsuhashi N, Futamura M, **Akao Y**, Yoshida K. Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase. *Int J Mol Sci.* 20(7), pii:E1697, 2019. (IF:3.687, CS:4.32) 査読あり
32. Takai T, Tsujino T, Yoshikawa Y, Inamoto T, Sugito N, Kuranaga Y, Heishima K, Soga T, Hayashi K, Miyata K, Kataoka K, Azuma H, **Akao Y**. Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo. *Mol Ther.* 27(5):1017-1027, 2019. (IF:7.008, CS:6.05) 査読あり
33. Kagota S, Taniguchi K, Lee SW, Ito Y, Kuranaga Y, Hashiguchi Y, Inomata Y, Imai Y, Tanaka R, Tashiro K, Kawai M, **Akao Y**, Uchiyama K. Analysis of Extracellular Vesicles in Gastric Juice from Gastric Cancer Patients. *Int J Mol Sci.* 20(4), pii: E953, 2019. (IF:3.687, CS:4.32) 査読あり
34. Shinohara H, Sugito N, Kuranaga Y, Heishima K, Minami Y, Naoe T, **Akao Y**. Potent antiproliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation. *Cancer Sci.* 110(2):751-760, 2019. (IF:4.372, CS:4.60) 査読あり
35. Shinohara H, Minami Y, Naoe T, **Akao Y**. Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein. *Haematologica.* pii: haematol.2018.194431, 2018. (IF:9.090, CS:4.07) 査読あり
36. Kuranaga Y, Sugito N, Shinohara H, Tsujino T, Taniguchi K, Komura K, Ito Y, Soga T, **Akao Y**. SRSF3, a Splicer of the PKM Gene, Regulates Cell Growth and Maintenance of Cancer-Specific Energy Metabolism in Colon Cancer Cells. *Int J Mol Sci.* 19 (10), pii: E3012, 2018. (IF:3.687, CS:4.32) 査読あり

	<p>37. Inoue A, Kobayashi CI, Shinohara H, Miyamoto K, Yamauchi N, Yuda J, <b>Akao Y</b>, Minami Y. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. <i>Int J Hematol.</i> 108(4):365-370, Review, 2018. (IF:1.942, CS:1.89) 査読あり</p> <p>38. Nakamoto K, <b>Akao Y</b>, Furuichi Y, Ueno Y. Enhanced Intercellular Delivery of cRGD-siRNA Conjugates by an Additional Oligospermine Modification. <i>ACS Omega.</i> 3(7):8226-8232. 2018. (IF:2.584, CS:2.54) 査読あり</p> <p>39. Inamoto T, Uehara H, <b>Akao Y</b>, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tãnda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H. A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder. <i>Dis Markers.</i> 2018:5468672, 2018. (IF:2.949, CS:2.64) 査読あり</p> <p>40. Nakamoto K, <b>Akao Y</b>, Ueno Y. Diazirine-containing tag-free RNA probes for efficient RISC-loading and photoaffinity labeling of microRNA targets. <i>Bioorg Med Chem Lett.</i> pii:S0960-894X(18)30583-3, 2018. (IF:2.448, CS:2.50) 査読あり</p> <p>41. Tajirika T, Tokumaru Y, Taniguchi K, Sugito N, Matsushashi N, Futamura M, Yanagihara K, <b>Akao Y</b>, Yoshida K. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells. <i>Int J Mol Sci.</i> 19(7), pii: E2005, 2018. (IF:3.687, CS:4.32) 査読あり</p> <p>42. Taniguchi K, Sugito N, Shinohara H, Kuranaga Y, Inomata Y, Komura K, Uchiyama K, <b>Akao Y</b>. Organ-Specific MicroRNAs (<i>MIR122, 137, and 206</i>) Contribute to Tissue Characteristics and Carcinogenesis by Regulating Pyruvate Kinase M1/2 (<i>PKM</i>) Expression. <i>Int J Mol Sci.</i>, 24;19(5), pii:E1276, 2018. (IF:3.226) 査読あり</p> <p>43. Nakagawa Y, <b>Akao Y</b>, Tahara T, Yamashita H, Nagasaka M, Shibata T, Ohmiya N. Development and endoscopic appearance of colorectal tumors are characterized by the expression profiles of miRNAs. <i>Med Mol Morphol.</i>, 2018, 51(2):82-88, Review. (IF:1.210) 査読あり</p> <p>44. <b>Akao Y</b>, Kumazaki M, Shinohara H, Sugito N, Kuranaga Y, Tsujino T, Yoshikawa Y, Kitade Y. Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. <i>Cancer Sci.</i>, 2018. (IF:3.974) 査読あり</p> <p>45. Taniguchi K, Iwatsuki A, Sugito N, Shinohara H, Kuranaga Y, Oshikawa Y, Tajirika T, Futamura M, Yoshida K, Uchiyama K, <b>Akao Y</b>. Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells. <i>Mol Carcinog.</i> 2018. (IF:4.185) 査読あり</p>
<p><b>外部資金</b> (過去 5 年)</p>	<p>1. 次世代がん医療創生研究事業 (AMED; 2016-2021) DDS 技術を基盤とした革新的がん治療法の開発</p> <p>2. 橋渡し研究戦略的推進プログラム (2018-2019) (中部先端医療開発円環コンソーシアム) がん特異的エネルギー代謝を標的にした RNA 創薬</p>
<p><b>受賞</b></p>	<p>日本血液学会奨励賞 (1992 年) 盛記念学術賞 (1993 年) 日本白血病研究基金一般研究賞 (2004 年)</p>
<p><b>新聞報道</b> (過去 5 年)</p>	<p>令和 2年11月20日 週刊医学新聞 「RAS遺伝子を標的としたマイクロRNA核酸医薬の開発に成功」</p>
<p><b>略歴</b></p>	<p>昭和 53 年 3 月 大阪医科大学卒業</p> <p>昭和 53 年 4 月 名古屋第一赤十字病院内科 (骨髄移植)</p> <p>昭和 59 年 4 月 名古屋大学医学部第一内科、分院内科 (医学博士取得)</p> <p>昭和 63 年 9 月 米国ウイスター研究所 (Dr. Calro Croce)</p> <p>平成 2 年 9 月 名古屋大学医学部分院内科</p> <p>平成 3 年 4 月 愛知県がんセンター研究所 (化学療法部) 主任研究員</p> <p>平成 5 年 9 月 大阪医科大学 (解剖学) 助教授</p> <p>平成 8 年 7 月 岐阜県国際バイオ研究所部長</p> <p>平成 21 年 4 月 岐阜大学大学院連合創薬医療情報研究科教授</p> <p>平成 30 年 4 月 岐阜大学大学院連合創薬医療情報研究科特任教授</p>